Platelet-rich plasma is a key ingredient in ECI’s novel formulation.
human platelet-rich plasma
Platelet-rich plasma is a key ingredient in ECI’s novel formulation.
ECI is developing novel products with the goal of combining the tissue-repairing benefits of platelet-rich plasma-derived growth factors with the sustained action of hyaluronic acid, to provide both relief and long-lasting therapeutic action.
Platelet-rich plasma is also rich in growth factors and proteins. These components are known to promote cell proliferation, tissue regeneration, and repair, making them beneficial for healing and naturally hydrating dry mucosal membranes.
for eye care
The healing properties of platelet-rich plasma-derived growth factors are ideal for addressing the damaged ocular surface often associated with neurotrophic keratopathy (NK), dry eye disease (DED), ophthalmic burns, epithelial defects, endothelial diseases, limb stem cell deficiency, ocular GvHD, corneal abrasions, and chronic wounds. Platelet-rich plasma offers a semblance to the properties of natural tears. ECI’s innovative approach means that patients can experience alleviation from the uncomfortable, gritty sensations typical of eye drops. Another advantage of platelet-rich plasma is its potential anti-inflammatory effects, which directly tackle one of the root causes of multiple ophthalmic conditions.
for wound care
Platelet-rich plasma is abundant with growth factors, proteins, and other bioactive molecules, all of which are advantageous for the health of surface cells. The growth factors present in plasma can stimulate cell growth and significantly enhance wound healing.
for mucosal membranes
Platelet-rich plasma’s growth factors and proteins promote cell proliferation, tissue regeneration, and repair, potentially making them beneficial for mucosal health. Additionally, the inherent composition of plasma naturally hydrates dry mucosal membranes.
human plasma and safety
Plasma is collected at an FDA licensed blood center through a typical blood donation process.
Blood centers perform multiple safety tests before releasing any blood product for further processing or use. In addition, a licensed pathogen-inactivation (pathogen reduction) process and specialized filtration enhances the safety and quality of our products.
learn more about:
our products
Our therapeutic formulation is suitable for a variety of products, including liquid eye drops, gels, ointments, contact lenses, contoured bandages, and wound dressings. Initially, ECI is pursuing ophthalmic indications for neurotrophic keratopathy (NK) and dry eye disease (DED).
ECI’s pipeline includes indications for ophthalmic burns, epithelial defects, endothelial diseases, limb stem cell deficiency, ocular graft-versus-host disease (GvHD), corneal abrasions, and chronic wounds.
our patients
Patients who experience conditions ranging from neurotrophic keratitis (NK) to dry eye disease (DED), wounds, or burns may benefit from our fusion of plasma and HA as a forward-thinking and potent strategy to potentially address their conditions with easier access and fewer side effects.
our platform
Our platform leverages growth factors derived from donated human platelet-rich plasma and proprietary hyaluronic acid (HA) or chitosan. The tissue-repairing benefits of plasma-derived products, combined with the sustained action and impact of HA or chitosan, may provide relief and long-lasting therapeutic action.